Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Swain

Showing results (481-490 of 532) with videos related to

Pageof 54
Sort By:
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Clinical Breast Cancer|October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5John W Smith, Marc E Buyse, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Breast Cancer Research and Treatment|March 11, 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyF Lynce, A Barac, X Geng, et al.
NPJ Breast Cancer|September 30, 2024
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA studyIlana Schlam, D Max Smith, Cody Peer, et al.
JAMA|June 6, 2013
Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trialSayeed Ikramuddin, Judith Korner, Wei-Jei Lee, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Pageof 54

Showing results (481-490 of 532) with videos related to

Sort By:
Pageof 54
JNCI Cancer Spectrum|November 26, 2020
Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831Katherine L Pogue-Geile, Nan Song, Daniel J Serie, et al.
Clinical Breast Cancer|October 4, 2016
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5John W Smith, Marc E Buyse, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerSuparna Bonthala Wedam, Jennifer A Low, Sherry X Yang, et al.
Breast Cancer Research and Treatment|March 22, 2023
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41Priya Rastogi, Gong Tang, Saima Hassan, et al.
The Oncologist|December 2, 2025
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studiesYeon Hee Park, Javier Cortes, Shanu Modi, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Breast Cancer Research and Treatment|March 11, 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt studyF Lynce, A Barac, X Geng, et al.
NPJ Breast Cancer|September 30, 2024
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA studyIlana Schlam, D Max Smith, Cody Peer, et al.
JAMA|June 6, 2013
Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trialSayeed Ikramuddin, Judith Korner, Wei-Jei Lee, et al.
Frontiers in Oncology|June 12, 2023
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trialPooja P Advani, Kathryn J Ruddy, Joerg Herrmann, et al.
Pageof 54